Ji‐Feng Feng

机构：Chinese Academy of Sciences, Zhejiang Cancer Hospital, Jiangsu Cancer Hospital, Hangzhou Cancer Hospital · ORCID：0000-0002-6983-1318

发表论文 71 篇 · 总被引 3022 次 · h-index 24

代表论文

• Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 154)
• Clinical significance of preoperative CALLY index for prognostication in patients with esophageal squamous cell carcinoma undergoing surgery (2024 · Scientific Reports · 被引 67)
• Clinical utility of preoperative pan-immune-inflammation value (PIV) for prognostication in patients with esophageal squamous cell carcinoma (2023 · International Immunopharmacology · 被引 29)
• Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS) (2024 · 癌症：英文版 · 被引 28)
• Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma (2023 · Annals of Surgical Oncology · 被引 27)
• Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores (2022 · Journal of Inflammation Research · 被引 18)